CloneID: ABT-325 (A-794722.0; 2.5(E))
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated by immunizing transgenic Xenomouse with human IL-18 in phosphate-buffered saline.
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format for improved compatibility with existing reagents assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: Q14116
Specificity Statement: This antibody binds human and cynomolgus monkey IL-18 and does not cross react with mouse, rat or dog IL-18. Interleukin-18 is a pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses.
Application Notes (Clone): The binding characterization of this antibody to human and cynomolgus monkey IL-18 was done using BIACORE assay. The binding affinity of the human IgG1 version was reported to be Kd=0.196 nM. This antibody can be used to immunoprecipitate human and cynomolgus monkey IL-18. This antibody neutralized both recombinant (KG-1 and RBA) and natural IL-18 (WBA) in an in vitro assay. The ability of this antibody to neutralize natural human IL-18-induced IFNγ in an inflammatory environment in vivo, the severe combined immunodeficient (SCID) mouse model was used wherein human PBMCs were injected into the mouse and the cells were stimulated in vivo to produce human IL-18 (HuPBMC-SCID model). This antibody inhibited human IL-18-dependent human IFNγ production in vivo with a clear dose-response by either route of administration. The binding of C1q to this antibody was determined using standard ELISA techniques (US20050100965). This antibody was used in the generation of a dual variable domain immunoglobulin (DVD-Ig) in combination with anti-IL-12 antibody for therapeutic use for targeting disease where multiple mediators contribute to overall disease pathogenesis (PMID: 17934452).
English
Deutsch
